CARsgen Therapeutics Holdings Ltd
HKEX:2171
CARsgen Therapeutics Holdings Ltd
Current Portion of Long-Term Debt
CARsgen Therapeutics Holdings Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
CARsgen Therapeutics Holdings Ltd
HKEX:2171
|
Current Portion of Long-Term Debt
ÂĄ14.8m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Beigene Ltd
HKEX:6160
|
Current Portion of Long-Term Debt
ÂĄ358.8m
|
CAGR 3-Years
57%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
||
Innovent Biologics Inc
HKEX:1801
|
Current Portion of Long-Term Debt
ÂĄ1B
|
CAGR 3-Years
38%
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
||
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Current Portion of Long-Term Debt
ÂĄ13.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Current Portion of Long-Term Debt
ÂĄ61.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Imeik Technology Development Co Ltd
SZSE:300896
|
Current Portion of Long-Term Debt
ÂĄ15m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
CARsgen Therapeutics Holdings Ltd
Glance View
CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.
See Also
What is CARsgen Therapeutics Holdings Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
14.8m
CNY
Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Current Portion of Long-Term Debt amounts to 14.8m CNY.
What is CARsgen Therapeutics Holdings Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-42%
Over the last year, the Current Portion of Long-Term Debt growth was -33%. The average annual Current Portion of Long-Term Debt growth rates for CARsgen Therapeutics Holdings Ltd have been -42% over the past three years .